HighGravityDataCurrent guidance
8 items
Abbott Laboratories
Guidance from Abbott Laboratories’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Jul 16, 2026
Data checked
Jul 16, 2026
What changed in the Jul 16, 2026 release
Each item compared with the same item in the previous release (Apr 16, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Adjusted diluted earnings per share | for Q3 FY2026 | — | “$1.38 to $1.46” | Filing ↗ |
| New | Adjusted diluted earnings per share | for FY2026 | — | “$5.45 to $5.60” | Filing ↗ |
| New | Adjusted diluted earnings per share | for Q3 FY2026 | — | “$1.38 to $1.46” | Filing ↗ |
| New | Adjusted diluted EPS | for FY2026 | — | “$5.45 to $5.60” | Filing ↗ |
| Reiterated | Comparable sales growth | for FY2026 | “6.5% to 7.5%” | “6.5% to 7.5%” | Filing ↗ |
Show 1 item not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | New cardiovascular device manufacturing facility in Georgia | for FY2028 | “to be completed by 2028” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Comparable sales growth | “6.5% to 7.5%” | for FY2026 | Company-defined | Apr 16, 2026 | 2 | Filing ↗ |
| Adjusted diluted earnings per share | “$1.38 to $1.46” | for Q3 FY2026 | Company-defined | Jul 16, 2026 | 1 | Filing ↗ |
| Adjusted diluted earnings per share | “$5.45 to $5.60” | for FY2026 | Company-defined | Jul 16, 2026 | 1 | Filing ↗ |
| Adjusted diluted earnings per share | “$1.38 to $1.46” | for Q3 FY2026 | Company-defined | Jul 16, 2026 | 1 | Filing ↗ |
| Adjusted diluted earnings per share | “$5.38 to $5.58” | for FY2026 | Company-defined | Jan 22, 2026 | 2 | Filing ↗ |
| Adjusted diluted EPS | “$5.45 to $5.60” | for FY2026 | Company-defined | Jul 16, 2026 | 1 | Filing ↗ |
| Organic sales growth | “6.5% to 7.5%” | for FY2026 | Company-defined | Jan 22, 2026 | 1 | Filing ↗ |
| Quarterly dividend | “$0.63 per share” | for FY2026 | Declared action | Jul 16, 2026 | 1 | Filing ↗ |
Next year and medium term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| New cardiovascular device manufacturing facility in Georgia | “to be completed by 2028” | for FY2028 | Company-defined | Jul 17, 2025 | 1 | Filing ↗ |
How one item moved
Quarterly dividend, No period stated — every statement across the year, each linked to its filing.
How your Medical devices & equipment sector group guides
12 companies in Medical devices & equipment. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| Medtronic | Sep 1, 2026 | 3 changes |
| Becton Dickinson | Aug 6, 2026 | 4 changes |
| ResMed | Aug 6, 2026 | 0 changes |
| Insulet | Aug 5, 2026 | 25 changes |
| Zimmer Biomet | Aug 5, 2026 | 3 changes |
| DexCom | Jul 30, 2026 | 3 changes |
| Stryker | Jul 30, 2026 | 2 changes |
| Boston Scientific | Jul 29, 2026 | 5 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2028 | FY2026 | FY2025 | FY2024 | No period |
|---|---|---|---|---|---|
| Comparable sales growth | — | 2 statements | — | — | — |
| Adjusted diluted earnings per share | — | 9 statements | 5 statements | — | — |
| Adjusted diluted EPS | — | 1 statement | 3 statements | 2 statements | — |
| Adjusted operating margin | — | — | 3 statements | — | — |
| Diluted EPS (GAAP) | — | — | — | 1 statement | — |
The full record for Abbott Laboratories and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Jul 16, 2026 | FY2026 Q2 | 0001628280-26-048377 | 6 | Open filing ↗ |
| Apr 16, 2026 | FY2026 Q1 | 0001628280-26-025365 | 5 | Open filing ↗ |
| Jan 22, 2026 | FY2025 Q4 | 0001628280-26-002982 | 5 | Open filing ↗ |
| Oct 15, 2025 | FY2025 Q3 | 0001628280-25-045049 | 5 | Open filing ↗ |
| Jul 17, 2025 | FY2025 Q2 | 0001628280-25-035135 | 6 | Open filing ↗ |
| Apr 16, 2025 | FY2025 Q1 | 0001628280-25-017924 | 5 | Open filing ↗ |
| Jan 22, 2025 | FY2024 Q4 | 0001628280-25-002092 | 6 | Open filing ↗ |
| Oct 16, 2024 | FY2024 Q3 | 0001628280-24-042893 | 10 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error